This page lists the SEC filings reported by Manning Paul B.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2024-02-14 | Manning Paul B | Liquidia Corp | 6,328,721 | 9.2% | EDGAR |
| SC 13D/A | 2023-08-21 | Manning Paul B | Taysha Gene Therapies, Inc. | 23,476,333 | 12.6% | EDGAR |
| SC 13G/A | 2023-02-15 | Manning Paul B | Pasithea Therapeutics Corp. | 3,408,696 | 11.3% | EDGAR |
| SC 13G/A | 2023-02-14 | Manning Paul B | Liquidia Corp | 6,024,113 | 9.3% | EDGAR |
| SC 13G/A | 2023-02-14 | Manning Paul B | Acumen Pharmaceuticals, Inc. | 3,205,128 | 7.8% | EDGAR |
| SC 13D/A | 2022-11-02 | Manning Paul B | Taysha Gene Therapies, Inc. | 6,989,861 | 11.2% | EDGAR |
| SC 13D | 2022-07-15 | Manning Paul B | Verrica Pharmaceuticals Inc. | 15,389,481 | 37.4% | EDGAR |
| SC 13G | 2022-06-29 | Manning Paul B | Pasithea Therapeutics Corp. | 2,608,696 | 9.8% | EDGAR |
| SC 13G | 2022-02-15 | Manning Paul B | Acumen Pharmaceuticals, Inc. | 4,010,678 | 9.9% | EDGAR |
| SC 13D | 2022-02-14 | Manning Paul B | Candel Therapeutics, Inc. | 4,073,316 | 13.6% | EDGAR |
| SC 13G/A | 2022-02-14 | Manning Paul B | Liquidia Corp | 5,175,172 | 10.0% | EDGAR |
| SC 13G/A | 2022-02-14 | Manning Paul B | Verrica Pharmaceuticals Inc. | 10,627,577 | 38.6% | EDGAR |
| SC 13G/A | 2021-02-16 | Manning Paul B | Verrica Pharmaceuticals Inc. | 9,837,747 | 38.0% | EDGAR |
| SC 13G | 2021-02-16 | Manning Paul B | Liquidia Corp | 4,942,041 | 11.4% | EDGAR |
| SC 13D | 2020-10-05 | Manning Paul B | Taysha Gene Therapies, Inc. | 5,295,307 | 14.3% | EDGAR |
| SC 13G/A | 2020-02-03 | Manning Paul B | Verrica Pharmaceuticals Inc. | 9,643,247 | 37.4% | EDGAR |
| SC 13G/A | 2019-02-06 | Manning Paul B | Dova Pharmaceuticals Inc. | 14,666,180 | 52.0% | EDGAR |
| SC 13G | 2019-02-06 | Manning Paul B | Verrica Pharmaceuticals Inc. | 9,574,861 | 37.3% | EDGAR |
| SC 13G | 2018-02-13 | Manning Paul B | Dova Pharmaceuticals, Inc. | 14,124,049 | 55.1% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.